| 1 |
33120790 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. | 2020 Oct 23 |
1 |
| 2 |
30307354 | Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. | 2019 |
1 |
| 3 |
30739089 | A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. | 2019 Feb 9 |
1 |
| 4 |
31126331 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. | 2019 May 24 |
1 |
| 5 |
24889488 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. | 2015 Jan |
1 |
| 6 |
25605843 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Mar 1 |
1 |
| 7 |
25870609 | Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. | 2015 |
1 |
| 8 |
25937522 | FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Jul |
1 |
| 9 |
24692733 | Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. | 2014 Apr |
2 |
| 10 |
24764659 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. | 2014 Apr 21 |
1 |
| 11 |
24764664 | Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. | 2014 Apr 21 |
1 |
| 12 |
23689915 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. | 2013 Jul |
1 |
| 13 |
22740893 | Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation. | 2012 Feb |
1 |
| 14 |
20972872 | Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. | 2011 Aug |
1 |
| 15 |
21228335 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. | 2011 Jul |
1 |
| 16 |
21502544 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. | 2011 May 20 |
1 |
| 17 |
21635994 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. | 2011 Apr |
2 |
| 18 |
21855038 | An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. | 2011 Sep |
1 |
| 19 |
22811812 | KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. | 2010 Dec |
1 |
| 20 |
9816002 | Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival | 1995 Apr |
1 |